The team

In addition to the position of CEO, Anna Steneholm, PhD in Respiratory Toxicology, ERT, provides support in drug development and risk assessment of chemicals, with senior expertise in EU chemical regulations (REACH & CLP) and interaction with regulatory authorities.

Stefan Czene, PhD in Oncology, provides support in risk assessment of impurities, reagents and intermediates, with long experience in genetic toxicology and (Q)SAR analysis.

Eva-Lena Glämsta, PhD in Pharmacology, ERT, provides support in drug development, with senior expertise in project management and interaction with regulatory authorities.

Hallgrimur Jonasson, PhD in Physiology, Associate professor, ERT, provides support in drug development and study outsourcing, with senior expertise in safety pharmacology.

Lizette Granberg, PhD in Environmental Toxicology, ERT, provides support in drug development and risk assessment of chemicals, with extensive experience in general toxicology.

Hanna Andersson, MSc in Pharmacy (research project in genetic toxicology). Provides support in the risk assessment of extractables and leachables (E&L), derivation of OEL/PDEs and study monitoring as well as assisting Sr. Toxicologists in drug development projects.

Axel Erbing, PhD in Chemical Physics, Provides support in risk assessment of chemicals, in silico predictions, statistics, product development and regulatory compliance under REACH and CLP.

Anna Sandholm, PhD in Environmental Chemistry (focus on Metabolism, Pharmacokinetic and safety evaluation), provides support in drug development and regulatory science with senior expertise in project management and interaction with regulatory authorities.

Erik Bivehed, PhD in Genetic Toxicology, provides support in risk assessment of impurities, reagents and intermediates, with expertise in genetic toxicology, in vitro testing strategies and application of (Q)SAR modelling.